



COUNTY OF SAN LUIS OBISPO HEALTH AGENCY
PUBLIC HEALTH DEPARTMENT
PROVIDER HEALTH ADVISORY

Date: December 24, 2024

Contact: Rick Rosen, MD, MPH, frosen@co.slo.ca.us, 805-781-5500

Mpox Treatment, Tecovirimat, Now Only Indicated for Patients at Risk of Severe Disease

The California Department of Public Health (CDPH) is sharing recommendations for providers following the recent end of the Study of Tecovirimat for Mpox (STOMP) clinical trial. After an [interim analysis](#) showed that – while tecovirimat was safe – it did not reduce pain or shorten the time to lesion resolution compared to placebo among adults with mild to moderate clade II mpox and a low risk of developing severe disease. Findings from this trial as well as the [PALM007](#) trial in the Democratic Republic of the Congo suggest that most patients with mpox who do not have severe disease or risk factors for severe disease (e.g., severe immunocompromise) will recover with supportive care, including pain management.

CDC's [Interim Clinical Considerations for Severe Manifestations of Mpox](#) provide guidance for managing patients who have or are at risk for protracted or life-threatening mpox due to severe immunocompromise. Providers can consider initiating tecovirimat in combination with other therapeutics (e.g., oral brincidofovir, IV cidofovir, or Vaccinia Immune Globulin IV) in these patients.

Tecovirimat remains available for treating mpox in patients who are eligible under the [CDC's EA-IND protocol](#) (e.g., persons with or at high risk for protracted or life-threatening disease as well as pregnant or lactating persons and children, regardless of disease severity or underlying comorbidities) through the Strategic National Stockpile and any previously deployed supply.

The County of San Luis Obispo Public Health Department continues to have a small supply of oral tecovirimat **available by request** and can also guide providers in obtaining intravenous tecovirimat. To request tecovirimat, contact Heidi Holmes-Nagy by calling 805-781-5535 or emailing hholmesnagy@co.slo.ca.us.

For additional questions about tecovirimat or other treatment for mpox, contact mpxtreatment@cdph.ca.gov.

Public Health Department

2191 Johnson Avenue | San Luis Obispo, CA 93401 | (P) 805-781-5500 | (F) 805-781-5543

www.slopublichealth.org